Sorafenib-Induced Acute Pancreatitis: Case Report and Review of the Literature
- 81 Downloads
Hepatocellular carcinoma (HCC) is the most common primary liver cancer and is the third leading cause of cancer-related death worldwide . The reported annual incidence of HCC is rising in most countries, mostly due to the increasing burden of chronic hepatitis B and hepatitis C virus (HCV), along with the prevalence of other risk factors such as excessive alcohol consumption. Although new HCV therapies have proven effective, they are often expensive and not always universally accessible. Additionally, the increased incidence of non-alcoholic fatty liver disease secondary to obesity and diabetes contribute to new cases of HCC, especially in developed countries such as the USA [2, 3, 4].
The Barcelona Clinic Liver Cancer (BCLC) Classification is the gold-standard guideline for managing patients with HCC . Early stages of HCC can be successfully managed with different treatment modalities, including hepatic resection, liver transplantation, and ablative therapies....
No funding was provided for the publication of this article, and the authors report no conflicts of interest.
Compliance with Ethical Standards
Informed consent was obtained from the patient for publication of this case report and any accompanying images.
- 1.DynaMed [Internet]. Ipswich (MA): EBSCO Information Services. 1995 -. Record No. 113622, Hepatocellular carcinoma; [updated 2016 Feb 15, cited February 9, 2017]; [about 24 screens]. Available from http://search.ebscohost.com/login.aspx?direct=true&db=dnh&AN=113622&site=dynamed-live&scope=site. Registration and login required.Google Scholar
- 7.Saadati H, Saif MW. Sorafenib-induced acute pancreatitis. JOP. 2010;11(3):283–4.Google Scholar
- 10.Llovet J, et al. Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a phase III randomized placebo-controlled trial (SHARP trial). Proceedings from the American Society of Clinical Oncology Conference: Chicago, IL; 2007.Google Scholar
- 16.Olayode A, Kizer R. Acute pancreatitis secondary to sorafenib use. Am J Gastroenterol. 2013;108(1):S262.Google Scholar
- 18.Reig M, Forner A, Rimola J, de Lope CR, Ayuso C, Llovet JM, et al. 815 sorafenib for the treatment of advanced hepatocellular carcinoma. Feasibility and safety outside research trials. J Hepatol [Internet]. European Association for the Study of the Liver. 2009;50:Se298. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0168827809608175 Google Scholar
- 19.ECOG performance status: http://ecog-acrin.org/resources/ecog-performance-status
- 24.Ferrario C, Strepponi I, Esfahani K, Charamis H, Langleben A, Scarpi E, et al. Phase I/II trial of sorafenib in combination with vinorelbine as first-line chemotherapy for metastatic breast cancer. PLoS One 2016;11(12):1–14.Google Scholar
- 25.Kitamura Y, Yoshii H, Nishimoto K, Shinchi Y, Tokonabe S, Takao M, et al. A case of pancreatic side effects resulting from sorafenib and axitinib treatment of stage IV renal cell carcinoma. Keio J Med. 2015;64(4):62–4.Google Scholar
- 27.Pezzilli R, Corinaldesi R, Morselli-Labate AM. Tyrosine kinase inhibitors and acute pancreatitis. JOP. 2010;11:291–3.Google Scholar